In a subgroup analysis it was found that patients with low-grade carcinoma and less aggressive tumour features showed reduced benefit from BEV treatment compared with those in the more aggressive, high-grade group.28 Based on our observations, tumours of the low-grade subgroup are likely to have high endothelial FABP4 expression. This evidence concerns the gene FABP4 and carcinoma.